A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service

References

• Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333-42
   PubMed Web of Science ®Google Scholar
• Lavanchy D. The global burden of hepatitis C. Liver Int 2009;29(1 Suppl):74-81
   PubMed Web of Science ®Google Scholar
• European Centres for Disease Prevention and Control. Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies. Stokholm 2010
   Google Scholar
• Centers for Disease Control and Prevention. Hepatitis C FAQs for health professionals. http://www.cdc.gov/hepatitis/hcv/hcvfaq.htm#. Accessed March 27, 2015
   Google Scholar
• Thomson EC, Fleming VM, Main J, et al. Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut 2011;60:837-45
   PubMed Web of Science ®Google Scholar
• Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment induced viral clearance. Gastroenterology 2003;125:80-8
   PubMed Web of Science ®Google Scholar
• Tong MJ, el-Farra NS, Reikes AR, et al. Clinical outcomes after transfusionassociated hepatitis C. New Engl J Med 1995;332:1463-6
   PubMed Web of Science ®Google Scholar
• Tremolada F, Casarin C, Alberti A, et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 1992;16:273-81
   PubMed Web of Science ®Google Scholar
• Thein HH, Yi Q, Dore GJ, et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008;48:418-31
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76
   PubMed Web of Science ®Google Scholar
• Ly KN, Xing J, Klevens RM, et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012;156:271-8
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Guidelines for the screening, care and treatment of persons with hepatitis C infection. Geneva: World Health Organisation, 2014
   Google Scholar
• Chou R, Hartung D, Rahman B, et al. Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Ann Intern Med 2013;158:114-23
   PubMed Web of Science ®Google Scholar
• Fried M, Buti M, Dore G et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013;58:1918-29
   PubMed Web of Science ®Google Scholar
• Jacobson I, Dore G, Foster G, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naive patients: The phase 3, randomised, double-blind, placebo-controlled QUEST-1 trial. Lancet 2014;384:403-13
   PubMed Web of Science ®Google Scholar
• Manns M, Marcellin P, Poordad F, et al. Simeprevir (TMC435) with peginterferon α-2a or α-2b/ribavirin for the treatment of chronic HCV genotype 1 infection in treatment-naive patients: QUEST-2, a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2014;384:414-26
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014;146:430-41
   PubMed Web of Science ®Google Scholar
• Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with Peginterferon and Ribavirin leads to high rates of SVR in patients with HCV Genotype 1 who relapsed after previous therapy: a Phase 3 Trial. Gastroenterology 2014;146:1669-79
   PubMed Web of Science ®Google Scholar
• Reddy K, Zeuzem S, Zoulim F, et al. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. Lancet Infect Dis 2015;15:27-35
   PubMed Web of Science ®Google Scholar
• Wright M, Grieve R, Roberts J, et al. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess 2006;10:1-113
   Web of Science ®Google Scholar
• Shepherd J, Jones J, Hartwell D, et al. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2007;11:1-205
   PubMed Web of Science ®Google Scholar
• Hartwell D, Jones J, Baxter L, et al. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Health Technol Assess 2011;15:1-210
   Web of Science ®Google Scholar
• Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-93
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. CHMP assessment report OLYSIO International non-proprietary name: SIMEPREVIR Procedure No. EMEA/H/C/002777/0000. London 2014
   Google Scholar
• Taieb V, Pacou M, Van Sanden S, et al. Mixed treatment comparison (MTC) to assess the relative efficacy and safety of simeprevir in combination with PEG-interferon alpha and ribavirin in treatment-naïve patients infected with hepatitis C virus (HCV) genotype 1. Poster presentation at AASLD/EASL Special Conference on Hepatitis C. New York, 12-13 September 2014
   Google Scholar
• Taieb V, Pacou M, Van Sanden S, et al. Mixed treatment comparison (MTC) to assess the relative efficacy and safety of simeprevir in combination with PEG-interferon alpha and ribavirin in treatment-experienced patients infected with hepatitis C virus (HCV) genotype 1. Poster presentation at AASLD/EASL Special Conference on Hepatitis C. New York, 12-13 September 2014
   Google Scholar
• Chen J, Florian J, Carter W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013;144:1450-5
   PubMed Web of Science ®Google Scholar
• Townsend R, McEwan P, Kim R, et al. Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C. Value Health 2011;14:1068-77.
   PubMed Web of Science ®Google Scholar
• Fernandez-Rodriguez CM, Alonso S, Martinez SM, et al. Peginterferon Plus Ribavirin and Sustained Virological Response in HCV-Related Cirrhosis: outcomes and factors predicting response. Am J Gastroenterol 2010;105:2164-72
   PubMed Web of Science ®Google Scholar
• Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-32
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE). Final appraisal determination - Telaprevir for the treatment of genotype 1 chronic hepatitis C. London 2012
   Google Scholar
• Gemeinsamer Bundesausschuss (G-BA). MSD SHARP & DOHME GmbH. Dossier zur Nutzenbewertung. Modul 4. Boceprevir (VICTRELIS). Berlin 2011
   Google Scholar
• Ratcliffe J, Longworth L, Young T, et al. Assessing health-related quality of life pre- and post-liver transplantation: a prospective multicenter study. Liver transplantation. 2002;8:263-70
   PubMed Web of Science ®Google Scholar
• Thorlund K, Druyts E, El Khoury AC, et al. Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection. Clinicoecon Outcomes Res 2012;4:349-5
   PubMedGoogle Scholar
• Longworth L, Young T, Buxton M. Midterm cost-effectiveness of the liver transplantation program of England and Wales for three disease groups. Liver Transplantation 2003;9:1295-307
   PubMed Web of Science ®Google Scholar
• PSSRU. Unit costs of health and social care 2013. University of Kent, Canterbury, 2014
   Google Scholar
• San Miguel R, Gimeno-Ballester V, Mar J. Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: a systematic review of published literature. Expert Rev Pharmacoecon Outcomes Res 2014;14:387-402
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE). Final appraisal determination - Boceprevir for the treatment of genotype 1 chronic hepatitis C. London 2012
   Google Scholar
• Drummond M, Jefferson T. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996;313:275-83
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE). TA330 Sofosbuvir for treating chronic hepatitis C. London 2015
   Google Scholar
• Sarrazin C, Lathouwers E, Peeters M, et al. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Antiviral Res 2015;116:10-16
   PubMed Web of Science ®Google Scholar